Is
post-transplant cyclophosphamide — based haploidentical donor transplantation appropriate for racial and ethnic minority patients with hematologic cancers?
Now, the new multi-center study confirms that
the post-transplant cyclophosphamide is safe and effective for people who have received fully - matched bone marrow transplants.
The scientists began to use
post-transplant cyclophosphamide in clinical trials of fully matched bone marrow transplants in 2004.
Medical centers around the world now use the Johns Hopkins protocol of
post-transplant cyclophosphamide, and Luznik says the inexpensive drug is becoming increasingly mainstream in bone marrow transplant regimens.
Yet, scientists lacked an explanation for why
post-transplant cyclophosphamide effectively curtailed acute and chronic GVHD.
They found high levels of the regulatory T - cells in patients treated with
post-transplant cyclophosphamide, and lab - cultured cells survived cyclophosphamide treatment.
Luznik and his team inventoried types of immune cells present in the blood of bone marrow transplant patients treated with
post-transplant cyclophosphamide.
«Our findings may also lead to even wider acceptance of
post-transplant cyclophosphamide,» he said.